Restatement of multiple years and auditor involvement signals potential material weakness in internal controls. Watch for the amended filings to see the magnitude of the adjustments and any subsequent auditor opinion on controls.
Price Chart
Executive Summary
NervGen Pharma announced it will restate financial statements for FY2024, FY2025, and Q2 2026 due to non-cash valuation errors in stock options and derivative warrant liabilities. The restatement does not affect cash position, cash flow, or liquidity, but the non-reliance disclosure is a significant governance red flag that undermines credibility.
Key Facts
- Audit committee concluded previously issued audited financials for FY2024 and FY2025, and unaudited Q2 2026 interim financials, should no longer be relied upon.
- Errors involve non-cash valuation of stock options and derivative warrant liabilities, reducing stock-based compensation expense and warrant liabilities.
- Restatement has no impact on cash position, cash flow, or liquidity.
- Company will file amendments to Form 40-F for FY2025 and a Form 6-K for Q2 2026 to restate the affected periods.
- Discussed with both KPMG Canada (former auditor for affected periods) and KPMG US (current auditor).
Financial Impact
Non-cash adjustments to stock-based compensation and warrant liability valuations; no cash impact; restatement magnitude not yet quantified.
Risk Factors
- Potential material weakness or material weakness in internal control over financial reporting
- Potential SEC investigation or enforcement action
- Potential shareholder lawsuits alleging misrepresentation
- Potential delay in clinical development or regulatory milestones due to distraction
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001104659-26-111004 |
| Document: 0001104659-26-111004-index-headers.html | 0001104659-26-111004 |
| Document: 0001104659-26-111004-index.html | 0001104659-26-111004 |
| Document: 0001104659-26-111004.txt | 0001104659-26-111004 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 25, 2026 4w ago | 6-K | $1.88 $1.81 | ▲ +3.72% | ▲ +4.93% | $1.50 (+20.21%) |
Sep 25, 2026 4w ago | Press Release | $1.88 $1.81 | ▼ −3.72% | ▼ −4.93% | $1.50 (−20.21%) |
Sep 24, 2026 4w ago | 6-K | $2.02 $1.76 | ▼ −12.87% | ▼ −12.46% | $1.50 (−25.74%) |
Aug 13, 2026 10w ago | 6-K | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.50 (−14.77%) |
Aug 13, 2026 10w ago | Press Release | $1.76 $1.76 | · 0.00% | ▲ +1.96% | $1.50 (−14.77%) |
Jul 2, 2026 16w ago | 6-K | $2.12 $1.86 | ▲ +12.26% | ▲ +13.19% | $1.50 (+29.25%) |
Jun 1, 2026 21w ago | 6-K | $2.00 $1.81 | ▲ +9.50% | ▲ +6.54% | $1.50 (+25.00%) |
May 27, 2026 21w ago | EFFECT | $2.07 $1.91 | ▼ −7.73% | ▼ −8.20% | $1.50 (−27.54%) |
May 26, 2026 21w ago | 6-K | $2.07 $2.00 | ▼ −3.38% | ▼ −4.59% | $1.50 (−27.54%) |
May 22, 2026 22w ago | 6-K | $2.13 $2.00 | ▲ +6.10% | ▲ +7.32% | $1.50 (+29.58%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers